Press Releases
Novozymes Biopharma’s rAlbumin approved in Japan as MAQUET expands into new market
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that one of its leading customers has achieved approval of a...
Press Releases
Promethera Biosciences opens the French part of its clinical trial in cell therapy
Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea...
Press Releases
Trophos announces positive interim review in pivotal study of olesoxime in Spinal Muscular Atrophy
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announces...
Press Releases
Okairos Initiates Phase I Clinical Trial Evaluating Vaccine against RSV Infections
Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital...
Press Releases
Quinten identifies a combination of two synergistic markers that predicts a favorable response to treatment in triple-negative breast cancer
Quinten, a strategic and operational consulting company specializing in the evaluation of biomedical data in the pharmaceutical, biotechnology and cosmetic industries, today announces the...
Press Releases
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection
Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) today have decided to voluntarily recall all lots of OMONTYS® (peginesatide) Injection to the user level...
Press Releases
Shimojani Licenses New Stroke Therapy from Niigata University
Shimojani LLC, a privately held biotech company, today announced that it has acquired an exclusive license from Niigata University for worldwide development and commercialization...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.